Patents by Inventor Leona E. Ling
Leona E. Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158508Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.Type: ApplicationFiled: July 13, 2023Publication date: May 16, 2024Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
-
Publication number: 20240158509Abstract: The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolismin a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: ApplicationFiled: August 18, 2023Publication date: May 16, 2024Inventors: Leona E. Ling, Darrell Nix, Nicholas A. Cilfone
-
Publication number: 20240052040Abstract: Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.Type: ApplicationFiled: April 19, 2023Publication date: February 15, 2024Inventors: Birgit C. Schultes, Chia Lin Chu, Laura Rutitzky, Lynn Zhang, Leona E. Ling
-
Patent number: 11773168Abstract: The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: GrantFiled: December 13, 2018Date of Patent: October 3, 2023Assignee: MOMENTA PHARMACEUTICALS, INC.Inventors: Leona E. Ling, Darrell Nix, Nicholas A. Cilfone
-
Patent number: 11732047Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.Type: GrantFiled: March 20, 2020Date of Patent: August 22, 2023Assignee: MOMENTA PHARMACEUTICALS, INC.Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
-
Patent number: 11661456Abstract: Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.Type: GrantFiled: May 21, 2018Date of Patent: May 30, 2023Assignee: Momenta Pharmaceuticals, Inc.Inventors: Birgit C. Schultes, Chia Lin Chu, Laura Rutitzky, Lynn Zhang, Leona E. Ling
-
Publication number: 20230049725Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: ApplicationFiled: April 28, 2022Publication date: February 16, 2023Inventors: Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
-
Publication number: 20220267413Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or a 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.Type: ApplicationFiled: May 9, 2022Publication date: August 25, 2022Inventors: Thomas E. Prod`Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
-
Patent number: 11352415Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.Type: GrantFiled: November 1, 2019Date of Patent: June 7, 2022Assignee: Momenta Pharmaceuticals, Inc.Inventors: Thomas E. Prod'Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
-
Patent number: 11345751Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: GrantFiled: July 31, 2017Date of Patent: May 31, 2022Assignee: MOMENTA PHARMACEUTICALS, INC.Inventors: Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
-
Publication number: 20220153833Abstract: The present invention relates to methods of using biologically active Fc domain-containing therapeutic constructs (Fc constructs) to induce immune cell activation of the immune response in a subject, and for example, to treat diseases such as cancers and infections in a subject. Such Fc constructs may include 5 or more Fc domains.Type: ApplicationFiled: March 2, 2017Publication date: May 19, 2022Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky, Birgit C. Schultes
-
Publication number: 20220064290Abstract: The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: ApplicationFiled: December 13, 2018Publication date: March 3, 2022Inventors: Leona E. Ling, Darrell Nix, Nicholas A. Cilfone
-
Publication number: 20220033499Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.Type: ApplicationFiled: August 20, 2021Publication date: February 3, 2022Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
-
Patent number: 11124573Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.Type: GrantFiled: March 25, 2019Date of Patent: September 21, 2021Assignee: Janssen Biotech, Inc.Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
-
Publication number: 20210238275Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: ApplicationFiled: July 31, 2017Publication date: August 5, 2021Inventors: Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
-
Publication number: 20210116462Abstract: The present invention relates to the determination of levels or expression of particular biomarkers in biological samples which can be utilized to diagnose, prognose, and treat Kawasaki disease in subjects, and further to select subjects who would benefit from a Kawasaki disease therapy other than, or in addition to, IVIG treatment. Accordingly, the present invention encompasses methods and compositions that utilize these biomarkers for the diagnosis, prognosis, and treatment of Kawasaki disease.Type: ApplicationFiled: April 6, 2020Publication date: April 22, 2021Inventors: Dorota A. Bulik, Carlos J. Bosques, Jay Duffner, Leona E. Ling, Hetal Sarvaiya
-
Publication number: 20200299382Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.Type: ApplicationFiled: March 20, 2020Publication date: September 24, 2020Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
-
Patent number: 10676526Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.Type: GrantFiled: January 29, 2016Date of Patent: June 9, 2020Assignee: Momenta Pharmaceuticals, Inc.Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
-
Publication number: 20200087402Abstract: Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.Type: ApplicationFiled: November 19, 2019Publication date: March 19, 2020Inventors: Birgit C. Schultes, Chia Lin Chu, Laura Rutitzky, Lynn Zhang, Leona E. Ling
-
Publication number: 20200055921Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.Type: ApplicationFiled: November 1, 2019Publication date: February 20, 2020Inventors: Thomas E. Prod`Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya